Automating Delirium Severity in the ICU

NCT ID: NCT06172491

Last Updated: 2025-04-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-15

Study Completion Date

2026-12-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to develop a passive digital marker (PDM) for delirium severity and examine its performance in comparison to validated delirium severity tools in ICU patients \>50 years of age.

The main questions it aims to answer are:

* Is the trained convolutional neural network able to reliably measure delirium severity.
* Is the Passive Digital Marker able to accurately measure delirium severity
* Is the Passive Digital Marker acceptable and usable by frontline ICU nurse clinicians, patients, and their identified proxies (i.e., caregivers).

Participants will:

* Study participation involves a video camera recording you 24 hours per day while you are a patient in the Intensive Care Unit (ICU).
* Study staff will visit you 4 times each day you are in the ICU. You will be asked questions each time they visit to train the digital marker and see differences between assessments and camera data.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bedside cameras will stay up for at least 72 hours (about 3 days), it may be longer if delirium is being experienced and if the patient and or LAR (Legally Authorized Representative) agree to the cameras' continued recording.

The study team will come and ask the patient questions 4 times daily. We will ask questions about their general, mental, and emotional health, their mood and memory. During these visits, the study team will check the alertness of the patient. Alertness will be checked by voice; if they do not respond, we will tap their shoulder gently. We will ask the patient to do activities like remembering words and saying them back, shaking hands, and drawing an object or clock. The study team will administer assessments 4 times daily. Participants will be asked questions about their general, mental, and emotional health, as well as mood and memory. While performing these sessions, the study team will observe the level of awareness. Awareness will be assessed by voice; if they do not respond, we will have to do a gentle tap on their shoulders. The patient will be asked to perform activities such as: remembering words and repeating them back, handshaking, and drawing an object or clock.

In some cases, if the patient's level of awareness alertness is lowered, we will do observation only perform observation assessments. These assessments do not interfere with clinical care. Participation in this study is voluntary.

The study team will continue to follow the patient until discharged from ICU.

The bedside nurse, patient, or family can cover the cameras with a washcloth if needed for privacy. The faces of family and clinicians and the bathing suit areas of patients are blurred before analysis to protect privacy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intensive Care Unit Delirium Encephalopathy Delirium

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No Delirium Severity

Patients who did not experience a level of delirium severity (subsyndromal, mild, moderate, severe)

No interventions assigned to this group

Delirium Severity

Patients who did experience a level of delirium severity (subsyndromal, mild, moderate, severe)

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Estimated length of stay \>24 hours in ICU; and
* Are not admitted for acute alcohol intoxication, drug (prescribed or illicit) overdose or withdrawal.

Exclusion Criteria

* Admitted for acute alcohol intoxication, drug (prescribed or illicit) overdose or withdrawal.
* Admitted for acute neuronal injury
* Unable to communicate with research team due to sensory deficits (aphasic, blind, deaf) or language (does not speak English)
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mayo Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Heidi L. Lindroth PhD RN

Heidi L. Lindroth, Ph.D., Nurse Scientist, Assistant Professor of Nursing

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic

Rochester, Minnesota, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Heidi Lindroth, PH.D. R.N.

Role: CONTACT

507-284-3662

Hannah Friesen

Role: CONTACT

1-507-284-2197

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hannah Friesen

Role: primary

507-284-2197

References

Explore related publications, articles, or registry entries linked to this study.

Raghu R, Nalaie K, Ayala I, Morales Behaine JJ, Garcia-Mendez JP, Friesen H, Leistikow K, Bhattacharyya A, Jayaraman A, Franco PM, Rabinstein A, Chlan LL, Boustani M, Herasevich V, Lindroth H. Harnessing the Power of Technology to Transform Delirium Severity Measurement in the Intensive Care Unit: Protocol for a Prospective Cohort Study. JMIR Res Protoc. 2025 Sep 25;14:e62912. doi: 10.2196/62912.

Reference Type DERIVED
PMID: 40998312 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

22-003098

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PupillOmetry for Prediction of DelirIUM
NCT05248035 ACTIVE_NOT_RECRUITING
Intelligent Intensive Care Unit
NCT02465307 ACTIVE_NOT_RECRUITING